LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Fechado

1.19 -3.25

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.19

Máximo

1.23

Indicadores-chave
By Trading Economics
Rendimento	3.5M -20M
EPS	-0.32
Funcionários	49
EBITDA	6.8M -22M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+120.66% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-1.2M 73M
Abertura anterior	4.44
Fecho anterior	1.19

Pliant Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de mai. de 2026, 16:33 UTC

Ganhos

Grandes Movimentos do Mercado

Webull Shares Slide on 1Q Loss, Soaring Costs

22 de mai. de 2026, 21:10 UTC

Ganhos

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de mai. de 2026, 19:47 UTC

Ganhos

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 de mai. de 2026, 19:17 UTC

Conversa de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 de mai. de 2026, 19:10 UTC

Conversa de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 de mai. de 2026, 18:38 UTC

Conversa de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 de mai. de 2026, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 de mai. de 2026, 18:09 UTC

Conversa de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 de mai. de 2026, 17:58 UTC

Conversa de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 de mai. de 2026, 17:54 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

22 de mai. de 2026, 17:54 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 de mai. de 2026, 17:54 UTC

Conversa de Mercado

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 de mai. de 2026, 17:03 UTC

Conversa de Mercado

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 de mai. de 2026, 16:54 UTC

Conversa de Mercado

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de mai. de 2026, 16:16 UTC

Conversa de Mercado

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

22 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 de mai. de 2026, 15:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 de mai. de 2026, 15:42 UTC

Conversa de Mercado

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 de mai. de 2026, 15:35 UTC

Conversa de Mercado

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Comparação entre Pares

Variação de preço

Pliant Therapeutics Inc Previsão

Preço-alvo

By TipRanks

120.66% parte superior

Previsão para 12 meses

Média 2.67 USD 120.66%

Máximo 3 USD

Mínimo 2 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Pliant Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Pliant Therapeutics Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.